technology
Precision medicine with neuron specific targeting
using non-invasive brain delivery technology
The challenge of delivering oligonucleotides
to the central nervous system (CNS)






Alon
Chen
Scientific Vision
Michel Ben Horovitz
Chief executive officer
Sharon Manashirov
Head of Science
Andrés Montefeltro
Advisor
Fabio
Jung
Head of Strategy
Ruben
Pavia
Staff scientist
Professor Alon Chen is the President of Weizmann Institute of Science, Rehovot, Israel and a Director at the Max Planck Institute of Psychiatry, Munich Germany. Prof. Chen also serves as the Head of the Max Planck Society – Weizmann Institute of Science Laboratory for Experimental Neuropsychiatry and Behavioral Neurogenetics. Prof. Chen’s research focuses on the Neurobiology of Stress, particularly the mechanisms by which the brain is regulating the response to stressful challenges and how this response is linked to psychiatric disorders. His lab has made discoveries linking the action of specific stress-related genes with anxiety, depression, social behaviors and metabolism. Prof. Chen and his research team use both mouse genetic models and human patients to ultimately create the scientific groundwork for therapeutic interventions to treat stress-related emotional disorders such as anxiety, post-traumatic stress, anorexia nervosa, and depression.
Former CFO of RXZ Investimentos, an investment company focused on listed and private equities. Mr. Horovitz was also a founding partner of two Brazilian Hedge Funds; Skopos Administradora de Recursos and VIX Investimentos. Mr. Horovitz holds a B.S. in Metallurgical Engineering from Universidade de São Paulo.
Andrés is the CEO and co-founder of CUBIQ FOODS (2018-present), a leading Spanish foodtech company. He is also Managing partner of Lingea Management & Consulting firm, supporting companies in Business development and Oligonucleotide delivery program development. Before, as CEO, Senior Vice President, Research Head & Founder, of nLife Therapeutics (2006-2018, he has been involved in the development of oligonucleotides as therapeutic agents, published papers in the field of oligonculeotides for CNS therapies and issued the foundational patents. He holds a B.D. in Biotechnology from the Rosario University in Argentina and a PDD-2004 from IESE Business School (Spain).
MD from Federal University of Rio Grande do Sul Post Doctoral Fellow at The University of Texas MD Anderson Cancer Center MBA in Finance and Health Care Management from the Wharton School, University of Pennsylvania Founding Partner, One Partners
Our team
Añade aquí tu texto de cabecera
Añade aquí tu texto de cabecera
Añade aquí tu texto de cabecera
Añade aquí tu texto de cabecera
Añade aquí tu texto de cabecera
Añade aquí tu texto de cabecera
Añade aquí tu texto de cabecera
Lorem fistrum por la gloria de mi madre esse jarl aliqua llevame al sircoo. De la pradera ullamco qué dise usteer está la cosa muy malar. saber más.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.